Skip to content
Center of
Trial & Error
CommentaryVol. 2: Prespectives on ReproducibilityUpdated

We need another 3R rule: repeat, repeat, repeat!

Annika Hulten1 & Saara Rannanpää1

  1. 1Janssen-Cilag Oy, Vaisalantie 2, 02130, Espoo, Finland
Download PDF
More formats

Abstract

There is consensus within the scientific community that replication studies are scientifically sound and bring added value and reliability to any discovery. It is also widely acknowledged that replications are not as common as they perhaps should be. The reasons for this vary depending on the stakeholder - here we will discuss the matter from the perspective of the pharmaceutical industry. However, the views expressed here are our own and do not represent the official standpoint of our employer or the industry in general. We will focus this commentary on the issues related to replications of the clinical part of the drug development, as our expertise is most closely related to this area, but the matter is equally relevant and important in the pre-clinical domain.

Cite as

Annika Hulten & Saara Rannanpää (2021). We need another 3R rule: repeat, repeat, repeat!. Journal for Reproducibility in Neuroscience, 2.

License

We need another 3R rule: repeat, repeat, repeat! by Annika Hulten & Saara Rannanpää is licensed under Creative Commons Attribution-ShareAlike 4.0 International.

More from Vol. 2: Prespectives on Reproducibility

Commentary

Science communication of reproducibility

Sara E. Jager & Katja Kaurinkoski

The importance of reproducibility is a widely discussed topic within academia, and there is an increased awareness about the issues in reproducibility, as we start to more actively tackle it within different fields of the scientific community. Outside of academia, however, reproducibility isn’t as…

Read